{"article_id": "LCI_q1_2022.txt", "article": ["our cash position increased to more than $ 105 million as of september 30 , 2021 , up from approximately $ 93 million at june 30 , 2021 .", "the plan will be implemented in phases , and we expect we will be completed in about 18 months .", "key elements of the plan include , first , consolidating our manufacturing footprint from two facilities to 1 .", "ultimately , the plan is expected to result in a workforce reduction of approximately 11 % from current levels .", "another 3 % or so of the workforce , mainly at the plant , we expect not to replace as attrition occurs .", "in total , we anticipate cost savings approximately $ 20 million annually .", "we currently have approximately 12 andas pending at the fda , including partner products , plus three additional products that are approved and pending launch .", "we also have more than 20 products in development and expect to add more from both external and internal efforts .", "with regard to our large , durable partnered product pipeline , i 'll provide an update on two of the 5 , starting with our generic advair diskus product .", "the plan is expected to be completed in approximately 18 months and generate annual cost savings of approximately $ 20 million .", "for the 2022 first quarter , net sales were $ 101.5 million compared with $ 126.5 million for the first quarter of last year .", "gross profit was $ 20.6 million or 20 % of net sales compared with $ 34.4 million or 27 % of net sales for the prior year first quarter .", "interest expense increased to $ 12.8 million from $ 11.2 million .", "net loss was $ 10.6 million or $ 0.27 per share versus net income of $ 2.2 million or $ 0.06 per diluted share .", "adjusted ebitda was $ 10.0 million .", "at september 30 , 2021 , cash and cash equivalents totaled approximately $ 105 million , up from $ 93 million at june 30 .", "accordingly , we expect to maintain a healthy cash position of $ 80 million plus through the end of fiscal 2022 .", "as for our liquidity , we also have access to our $ 45 million credit facility , which to date , we have not drawn upon .", "for fiscal 2022 , we now expect net sales in the range of $ 370 million to $ 400 million , down from $ 400 million to $ 440 million .", "adjusted gross margin , as a percentage of net sales , of approximately 19 % to 21 % , down from approximately 23 % to 25 % .", "adjusted r&d expense in the range of $ 25 million to $ 28 million , down from $ 26 million to $ 29 million .", "adjusted sg&a expense ranging from $ 55 million to $ 58 million , down from $ 58 million to $ 61 million .", "adjusted interest expense of approximately $ 52 million , unchanged .", "the full year adjusted effective tax rate in the range of 22 % to 23 % , up from 21 % to 22 % .", "adjusted ebitda in the range of $ 22 million to $ 32 million , down from $ 40 million to $ 55 million .", "and lastly , capital expenditures to be approximately $ 10 million to $ 14 million , down from $ 12 million to $ 18 million ."], "summary_gold": "lannett revises down full - year guidance .<q>q1 adjusted loss per share $ 0.27 .<q>compname announces restructuring plan targeting $ 20 million in reduced expenses , to consolidate manufacturing operations and restructure research and development function .<q>sees 2022 net sales $ 370 million to $ 400 million .<q>lannett company - have revised our guidance down to reflect , in part , particularly competitive environment of our current base oral generics portfolio .<q>also announced a restructuring plan approved by board earlier this week .<q>restructuring retains core strategies , while further optimizing operations , improving efficiencies and reducing costs .<q>elements of plan , which is expected to be completed in about 18 months , includes consolidating manufacturing footprint .<q>plan includes reducing headcount and discontinuing future development programs targeting liquid generic medications .<q>lannett - current organizational workforce will be reduced by about 11 % , and other existing and anticipated future vacancies will not be filled .<q>plan is expected to result in a leaner , more focused organization and generate cost savings of approximately $ 20 million , annually .", "summary_pred": "at september 30 , 2021 , cash and cash equivalents totaled approximately $ 105 million , up from $ 93 million at june 30 .<q>adjusted gross margin , as a percentage of net sales , of approximately 19 % to 21 % , down from approximately 23 % to 25 % .<q>another 3 % or so of the workforce , mainly at the plant , we expect not to replace as attrition occurs .<q>in total , we anticipate cost savings approximately $ 20 million annually .<q>net loss was $ 10.6 million or $ 0.27 per share versus net income of $ 2.2 million or $ 0.06 per diluted share .<q>we currently have approximately 12 andas pending at the fda , including partner products , plus three additional products that are approved and pending launch .<q>adjusted ebitda was $ 10.0 million .<q>key elements of the plan include , first , consolidating our manufacturing footprint from two facilities to 1 .<q>adjusted interest expense of approximately $ 52 million , unchanged .<q>the plan will be implemented in phases , and we expect we will be completed in about 18 months .<q>as for our liquidity , we also have access to our $ 45 million credit facility , which to date , we have not drawn upon .<q>ultimately , the plan is expected to result in a workforce reduction of approximately 11 % from current levels .<q>interest expense increased to $ 12.8 million from $ 11.2 million .<q>with regard to our large , durable partnered product pipeline , i 'll provide an update on two of the 5 , starting with our generic advair diskus product .<q>for the 2022 first quarter , net sales were $ 101.5 million compared with $ 126.5 million for the first quarter of last year .", "len_article": 26, "len_summary_gold": 11, "len_summary_pred": 15, "len_sent_scores": 26}